FernandoCFervenzaMD

Nephrology • Rochester, MN

Glomerular Disease

Consultant Nephrologist

Join to view full profile

Dr. Fervenza is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fervenza's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Fax+1 507-266-7891

Summary

Fernando C. Fervenza, MD. D.Phil (Oxon – Jesus College). Is a Professor of Medicine at the Mayo Graduate School of Medicine, Rochester, MN, USA. He graduated in Medicine at the Pontificia Universidade Catolica do Rio Grande do Sul, Brasil. He underwent his clinical nephrology training at the Oxford Renal Unit from 1985 to 1991. Subsequent training included Post-doctoral Fellowship at Stanford University, USA (1993-1997). He is a Fellow of the American Society of Nephrology, Fellow of the American College of Physicians, past Member of the American Board of Internal Medicine, Nephrology section, Associate Editor of the Journal of the American of Nephrology and Up-To-Date Section Editor for Glomerular Disease. His area of interest is in pursuing patient-oriented research projects aiming to bring new bench research discoveries to the bedside treatment of patient with glomerular diseases.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1997 - 1999
Stanford Health Care-Sponsored Stanford UniversityFellowship, Nephrology, 1993 - 1997
University of OxfordPh.D., 1991
Federal University of Rio Grande do Sul School of MedicineClass of 1982

Certifications & Licensure

MN State Medical License 1998 - 2025
AL State Medical License 1996 - 2001
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

Fellow National Kidney Foundation, 2011
Laureate Award Department of Internal Medicine-Mayo Clinic, 2010
Laureate Award Mayo Clinic, 2010
Career Development Award Mayo Foundation, 2007
Fellow American College of Physicians, 2006
Program Committee Member NKF Meeting-Chicago, 2004
Fellow American Society of Nephrology, 2004
ENHANCE Award Department of Medicine, Mayo Foundation, 2003
ENHANCE Award Mayo Foundation, 2003
CT 20 Clinical Research Award Mayo Foundation, 2001, 2006
Outstanding Resident Achievement Award Mayo Clinic, 1999
Fellowship Award Satellite Dialysis Fund of Northern California, 1996
Travel Award for the International Society Nephrology Meeting American Society Nephrology, 1995
Travel Award American Society Nephrology, 1995
International Scientific Cooperation Initiative Marie Curie Fellowship Commission of European Communities, 1993
Peter Beaconsfield Prize in Physiological Sciences University of Oxford, 1988
Peter Beaconsfield Prize in Physiological Sciences University of Oxford, England, 1988
Junior Author Award European Dialysis and Transplant Association, 1988-1989
Overseas Research Scholarship British Government, 1986
Overseas Research Scholarship otolaryngologic Clinics of North America, 1986
Fellow (ASNF) American Society of Nephrology
Join now to see all

Clinical Trials

Rituximab in the Treatment of Idiopathic Membranous Nephropathy Start of enrollment: 2006 Oct 01
Completed
Early Phase 1
CellCept in p-ANCA Vasculitis Start of enrollment: 2002 Dec 01
Completed
Phase 1
Rituxan in Churg Strauss Syndrome With Renal Involvement Start of enrollment: 2007 Jun 01
Terminated
Phase 2
Rituximab in Membranous Nephropathy Start of enrollment: 2004 Aug 01
Completed
Phase 2, Phase 3
Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Start of enrollment: 2009 Feb 01
Completed
Phase 4
Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy Start of enrollment: 2009 Jan 01
Completed
Phase 1
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial Start of enrollment: 2008 Dec 01
Completed
Phase 2
Aliskiren in Patients With Idiopathic Membranous Nephropathy Start of enrollment: 2010 Nov 01
Withdrawn
Not Applicable
MEmbranous Nephropathy Trial Of Rituximab Start of enrollment: 2011 Nov 01
Completed
Phase 2, Phase 3
Nephrotic Syndrome Study Network Start of enrollment: 2010 Apr 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

Updated diagnostic and therapeutic management for membranous nephropathy.
Fernando Caravaca-Fontán, Federico Yandian, Fernando C Fervenza
Current Opinion in Nephrology and Hypertension. 2025-01-01
Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial.
Matthew Kadatz, Scott Klarenbach, Helen So, Fernando C Fervenza, Daniel C Cattran
Nephrology, Dialysis, Transplantation. 2024-11-27
Lupus nephritis: redefining the treatment goals.
An S De Vriese, Sanjeev Sethi, Fernando C Fervenza
Kidney International. 2024-11-08

Journal Articles

CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report
Fernando C Fervenza, Karl A Nath, American Journal of Kidney Diseases
Congophilic Fibrillary Glomerulonephritis: A Case Series
Stephen B Erickson, Fernando C Fervenza, Nelson Leung, American Journal of Kidney Diseases
The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study
Musab S Hommos, Fernando C Fervenza, Mariam P Alexander, Mayo Clinic Proceedings
Rituximab for the Treatment of Relapses in ANCA-Associated Vasculitis
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Ikle D, Villareal M, Jepson B..., Arthritis Rheumatol, 7/21/2014
Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis
Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Am J Kidney Dis, 7/1/2014
Pathology of Renal Diseases Associated with Dysfunction of the Alternative Pathway of Complement: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome (aHUS)
Sethi S, Fervenza FC, Semin Thromb Hemost, 5/5/2014
Nephrotic Syndrome Redux: A Clinical Commentary
Glassock RJ, Fervenza FC, Hebert L, Cameron JS, Nephrol Dial Transplant, 4/10/2014
Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy?
Zand L, Fervenza FC, Nephrol Dial Transplant, 4/10/2014
A Pilot Study to Determine the Dose and Effectiveness of HPActhar® Gel in Subjects Nephrotic Syndrome due to Idiopathic Membranous Nephropathy
Hladunewich MA, Cattran DC, Beck LH, Sethi S, Leung N, Reich H, Fervenza FC, Nephrol Dial Transplant, 4/8/2014
Focal Segmental Glomerulosclerosis: Towards a better understanding for the practicing nephrologist
Sanjeev S, Glassock R, Fervenza FC, Nephrol Dial Transplant, 3/2/2014
Treatment of ANCA Vasculitis: New Therapies and a Look at Old Entities
Zand L, Specks U, Sethi S, Fervenza FC, Adv Chronic Kidney Dis, 3/1/2014
Nephrology Quiz and Questionnaire 2013
Fervenza FC, Palmer B, Mehrota R, Brennan P, Choi M, Perazella M, Clin J Am Soc Nephrol, 2/27/2014
Membranoproliferative Glomerulonephritis associated with Autoimmune Diseases
Zand L, Fervenza FC, Nasr SH, Sethi S, J Nephrol, 2/6/2014
Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis
Clain JM, Cartin-Ceba R, Fervenza FC, Specks U, Therapeutic Adv in Musc Dis, 1/1/2014
Clinical Findings, Pathology and Outcomes of C3 Glomerulonephritis following Kidney Transplantation
Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Smith RJH, Sethi S, J Am Soc Nephrol, 12/19/2013
C3 glomerulopathy: consensus report
Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fremeaux-Bacchi..., Kidney Int, 10/30/2013
Histologic classification of glomerular diseases: practical consequences for the clinician
Hass M, Fervenza FC, Ristaldi MP, Kidney Int, 10/2/2013
Frequently-Relapsing/Steroid-Dependent minimal change disease: is rituximab the answer?
Fervenza FC, Sethi S, Nephrol Dial Transplant, 9/11/2013
Treatment of idiopathic membranous nephropathy
Hofstra JM, Fervenza FC, Wetzels JFM, Nat Rev Nephrol, 8/1/2013
Maintenance of Rituximab-induced Remissions in ANCA-Associated Vasculitis
Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair W, Fessler B, Ding L, Webber L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D..., New Engl J Med, 8/1/2013
Attending Rounds: A patient with nephrotic-range proteinuria and focal global sclerosis on kidney biopsy
Fervenza FC, Clin J Am Soc Neph, 7/25/2013
"Clinical Outcomes of Remission Induction Therapy for Severe ANCA-Associated Vasculitis"
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, KallenbergCGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Ikle ..., Arthritis Rheum, 6/10/2013
Serum Soluble-Urokinase Receptor (suPAR) is Elevated in Kidney Transplant Candidates with Varied Causes of ESRD: Urinary suPAR Merits Further Study
Palacios CRF, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H, Transplantation, 6/3/2013
C3 Glomerulonephritis associated with Monoclonal Gammopathy
Zand L, Fervenza FC, Smith RJH, Zhang Y, Kattah A, Sethi S, Am J Kidney Dis, 4/25/2013
Nephrology Quiz and Questionnaire 2012
Fervenza FC, Palmer B, Mehrota R, Brennan P, Bleyer A, Glassock R, Clin J Am Soc Nephrol, 3/28/2013
Join now to see all

Books/Book Chapters

Core concepts in parenchymal kidney disease
Chapter: Preface
Fervenza FC, Lin J, Sethi S, Singh AKEditors: Fervenza FC; et al.Springer, New York, NY2014
Core concepts in parenchymal kidney disease
Chapter: Membranous nephropathy.
Page 51 - 75Fervenza FC, Passerini P, Sethi S, Ponticelli CEditors: Fervenza FC; et al.Springer, New York, NY2014
Core concepts in parenchymal kidney disease.
Chapter: Preface.
Fervenza FC, Lin J, Sethi S, Singh AKEditors: Fervenza FC; et al.Springer, New York, NY2014
Core Concepts in Parenchymal Kidney Disease.
Chapter: Membranoproliferative glomerulonephritis.
Page 77 - 85Sethi S, Fervenza FCEditors: Fervenza FC, Passerini P, Sethi S, Ponticelli C.Springer, New York, NY2014
Core Concepts in Parenchymal Kidney Disease.
Chapter: Membranous nephropathy.
Page 51 - 75Fervenza FC, Passerini P, Sethi S, Ponticelli CEditors: Fervenza FC, Passerini P, Sethi S, Ponticelli C.Springer, New York, NY2014
National Kidney Foundation's Primer on Kidney Diseases
Chapter: Membranous nephropathy.
Page 176 - 184Cattran DC, Fervenza FCEditors: Gilbert SJ; et al.Elsevier/Saunders, Philadelphia, PAEdition Sixt,2014
Mayo Clinic Internal Medicine Board Review
Chapter: Acute kidney injury, glomerular disease, and tubulointerstitial disease.
Page 551 - 566Norby SM, Kashani KB, Fervenza FCEditors: Ficalora RD; et al.Mayo Clinic Scientific Press, Rochester2013
Primer on Kidney Disease
Chapter: Membranous nephropathy.
Fervenza FC, Cattran DCElsevierEdition 6th,2013
Nephrology Secrets
Chapter: Membranous nephropathy.
Irazabal MV, Eirin A, Fervenza FCEditors: EV Lerma and AR Nissenson.Elsevier, Philadelphia, PAEdition 3rd,2012
Mayo Clinic Internal Medicine Board Review
Chapter: Evaluation of kidney function, glomerular disease, and tubulointerstitial disease.
Page 613 - 627Fervenza FCEditors: Ghosh AK; et al.Mayo Clinic Scientific Press, RochesterEdition 9th,2010
Current diagnosis & treatment, nephrology & hypertension
Chapter: Membranous nephropathy.
Page 229 - 241Fervenza FC, Cattran DCEditors: Lerma EV, Berns JS, Nissenson AR.McGraw-Hill Medical, New York, NY2009
Current Diagnosis and Treatment in Nephrology and Hypertension
Chapter: Membranous nephropathy.
Page 229 - 241Fervenza FC, Cattran DCEditors: Lerma EV, Berns JS, Nissenson AR.McGraw-Hill Medical, New York, NY2009
Evidence-based Nephrology
Chapter: Membranous nephropathy.
Page 158 - 169Fervenza FC, Cattran DCEditors: Molony DA, Craig JC.Hoboken: Wiley-Blackwell, Oxford2009
Mayo Clinic internal medicine: concise textbook
Chapter: Nephrology.
Page 569 - 611Fervenza FC, Schwab TR, Williams AW, Albright RC Jr, Erickson SBEditors: Habermann TM, Ghosh AK.Mayo Clinic Scientific Press, Rochester2008
Internal Medicine Review
Chapter: Glomerular and Tubulo-interstitial diseases.
Page 691 - 705Fervenza FC, Schwab TREditors: Ghosh AK.Mayo Clinic Scientific Press2008
Mayo Clinic Internal Medicine
Chapter: Nephrology
Page 569 - 611Fervenza FC, Schwab TR, Williams AW, Albright RC Jr, Erickson SBEditors: Habermann TM, Ghosh AK.Mayo Clinic Scientific Press, Rochester2008
Nefrologia no consultorio
Chapter: Membranous Nephropathy.
D. D'Avila and D. CattranEditors: Elvino Barros and Luis F. Goncalves.Artmed Editora S.A. Porto Alegre, RS, Brasil2007
Mayo Clinic Internal Medicine Review
Chapter: Nephrology.
Page 647 - 698Fervenza FC, Schwab TR, Williams AW, Albright RC Jr, Erickson SBEditors: Habermann TM.Mayo Clinic Scientific Press, RochesterEdition 7th,2007
Mayo Clinic Internal Medicine Review, 2006-2007
Chapter: Nephrology
Page 647 - 698Fervenza FC, Schwab TR, Williams AW, Albright RC Jr, Erickson SBEditors: Habermann TM.Mayo Clinic Scientific Press, RochesterEdition 7th,2006
Mayo Clinic Medical Manual
Chapter: Hematuria
Fervenza FC, Oxentenko AEditors: Guilherme H. M. Olivera, Gillian C. Nesbitt, Joseph G. Murphy.Taylor and Francis, MCS Press2006
Mayo Clinic Medical Manual
Chapter: Hematuria.
Fervenza FC, Oxentenko AEditors: Guilherme H. M. Olivera, Gillian C. Nesbitt, Joseph G. Murphy.Taylor and Francis, MCS Press2006
Current Diagnosis and Treatment in Nephrology and Hypertension
Chapter: Membranous Nephropathy
Fervenza FC, Cattran DCEditors: Edgar V. Lerma,MD, Allen R. Nissenson, M.D and Jeffrey S. Berns, MD.Lange Current Series2005
Colour Atlas of Renal Medicine
F.C. Fervenza, JP Grande, J Pattison, B Hartley, and D GoldsmithThieme, New York, NY2004
Mayo Clinic Internal Medicine Board Review Book
Chapter: Nephrology- Part I
Fernando Custodio Fervenza, MDEditors: T.H. Habermann.Lippincott Williams & Wilkins2004
Colour Atlas of Renal Medicine
Fervenza FC, JP Grande, J Pattison, B Hartley, and D GoldsmithThieme, New York, NY2004
Join now to see all

Abstracts/Posters

"Urinary Soluble Urokinase Receptor (suPAR) is Not Elevated in Membranous Nephropathy (MN) and Does Not Correlate with Proteinuria"
F.C. Fervenza, ASN, Philadelphia, 1/1/2014
"C3 Glomerulonephritis Associated With Autoimmune Disorders: A Case Series".
F.C. Fervenza, ASN, Philadelphia, 1/1/2014
"Impact of weight loss before renal transplantation in obese patients: risk of early mortality.
F.C. Fervenza, ASN, Philadelphia, 1/1/2014
C4d as a marker for Immune Complex-Mediated Glomerulonephritis versus C3 glomerulopathy.
F.C. Fervenza, ASN, Philadelphia, 1/1/2014
IgD Heavy Chain Deposition Disease: Detection by Laser Microdissection and Mass Spectrometry.
F.C. Fervenza, ASN, Philadelphia, 1/1/2014
Laser Microdissection and Mass Spectrometry of ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis Shows Accumulation of Components of the Alternative and Termina...
Sanjeev Sethi, MD, PhD, Julie A. Vrana, PhD, Ladan Zand, MD, Jason David Theis, Samih H. Nasr, MD, Fernando C. Fervenza, MD, PhD, FASN, ASN, Atlanta, 1/1/2013
IgA Nephropathy with ANCA seropisitivity: A case series.
Angela K. Muriithi, Lynn D. Cornell, Fernando C. Fervenza, Mary E. Fidler, Sanjeev Sethi, Samih H. Nasr, ASN, Atlanta, 1/1/2013
Recurrent C3 glomerulonephritis: clinicopathological findings and outcomes.
Ladan Zand, Elizabeth C. Lorenz, Fernando G. Cosio, Fernando C. Fervenza, Samih H. Nasr1, Richard J. Smith and Sanjeev Sethi, ASN, Atlanta, 1/1/2013
Nephrotic Syndrome Study Network Baseline Characteristics.
Gipson D, Troost J, Song P, Holzman LB, Sedor J, Cattran D, Fervenza F, Fornoni A, Kopp, J, Gadegbeku C, Adler S, Trachtman H, Nachman P, Neu A, Sethna C, Kaskel F, Ne..., ASN, Atlanta, 1/1/2013
The Prevalence of Circulating Monoclonal Protein in Proliferative Nephropathies with Monoclonal Deposits.
Gauri Bhutani, Fernando C. Fervenza, Sanjeev Sethi, Samih H. Nasr and Nelson Leung, ASN, Atlanta, 1/1/2013
A Randomized, placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephr...
F.C. Fervenza, E.T. Casey, J. J. Dillon, S. B. Erickson, M.C. Hogan, ASN, Atlanta, 1/1/2013
A multicenter, randomized, prospective, open-label trial of rituximab in the treatment of progressive IgA Nephropathy.
F.C. Fervenza, J.J. Dillon, S.B. Erickson, E.L. Greene, M.C. Hogan, ASN, Atlanta, 1/1/2013
A randomized controlled trial of rituximab (RTX) versus cyclosporine (CSA) in the treatment of idiopathic membranous nephropathy (IMN).
F.C. Fervenza, N. Aslam, L. Thomas, and D.C. Cattran for the investigators of the MENTOR, ASN, Atlanta, 1/1/2013
Laser Microdissection and Mass Spectrometry of ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis Shows Accumulation of Components of the Alternative and Termina...
Sanjeev Sethi, MD, PhD, Julie A. Vrana, PhD, Ladan Zand, MD, Jason David Theis, Samih H. Nasr, MD, Fernando C. Fervenza, MD, PhD, FASN, ASN, Atlanta, 1/1/2013
The Efficacy of Rituximab vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE TRIAL.
Geetha D, Fervenza FC for the RAVE-ITN Research Group, ASN, San Diego, 11/3/2012
A Pilot Study to Determine the Dose and Effectiveness of H.P.Acthar® Gel in Subjects Nephrotic Syndrome due to Idiopathic Membranous Nephropathy.
Fervenza FC, Cattran D, Beck LH, Reich H, Sethi S, Hladunewich MA, ASN, San Diego, 11/3/2012
Do anti-phospholipiase A2 receptor antibodies predict recurrence of membranous nephropathy after transplantation?
Ayalon R, Beck LH, Fervenza FC, Cosio FG, Brennan DC, Salant DJ, ASN, San Diego, 11/2/2012
The efficacy of rituximab vs cyclophosphamide for treatment of renal disease in anca-associated vasculitis: the rave trial Geetha D, Fervenza FC for the rave-itn resea...
Geetha D, Fervenza F, Arthritis Rheum, ACR/ARHP Annual Meeting, Washington, DC, 10/1/2012
Predictive value of selected markers of inflammation and platelet activation for complete remission in ANCA-associated vasculitis.
Tomasson G, Monach PA, Tanriverdi K, Specks U, Stone JH, Ding LN, Fervenza F, Hoffman GS, Kallenberg CGM, Langford CA, Phippard DJ, Seo P, Spiera RF, St Clair EW, Tcha..., Arthritis Rheum, ACR/ARHP Annual Meeting, Washington, DC, 10/1/2012
Treatment of membranous nephropathy with adrenocorticotropic hormone (acth) gel: correlation of anti-pla2r and disease activity.
Beck LH, Fervenza FC, Bomback AS, Ayalon R, Irazabal MV, Eirin A, Cattran DC, Appel GB, Salant DJ, Nephrol Dial Transplant, 5/1/2012
Lowand high molecular weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.
Irazabal MV, Eirin A, Lieske JC, Beck LH, Dillon JJ, Nachman PH, Sethi S, Erickson SB, Cattran DC, Fervenza FC, Nephrol Dial Transplant, 5/1/2012
C3 glomerulonephritis: clinicopathologic findings, complement abnormalities, glomerular proteomic profile, treatment and follow-up.
Sethi S, Fervenza FC, Vrana JA, Nasr SH, Zhang Y, Smith RJH, Lab Invest, 2/1/2012
C3 glomerulonephritis: clinicopathologic findings, complement abnormalities, glomerular proteomic profile, treatment and follow-up.
Sethi S, Fervenza FC, Vrana JA, Zhang Y, Nasr S, Smith RJ, Modern Pathology, 1/1/2012
Laser microdissection and proteomic analysis of amyloidosis, fibrillary and immunotactoid glomerulonephritis.
Sethi S, Vrana JA, Theis JD, Sethi A, Nasr SH, Cornell LD, Leung N, Fervenza FC, ASN, San Diego, 1/1/2012
Persistent' Post-Infectious Glomerulonephritis is associated with Abnormalities in the Alternative Pathway of Complement.
Sethi S, Fervenza FC, Zand L, Zhang Y, Nasr SH, Smith RJ, ASN, San Diego, 1/1/2012
Join now to see all

Lectures

"B-cell depletion in nephrotic syndrome"
San Francisco, CA - 7/18/2014
"Clinical presentation and treatment considerations in complement-mediated glomerular diseases"
National University of Ireland, Galway - 6/14/2014
"Membranous Nephropathy New Insights Regarding Diagnosis And Treatment"
University of Iowa, Iowa City - 6/4/2014
"Treatment of Membranous Nephropathy"
Santiago, Chile - 5/5/2014
"Remission-induction in ANCA-associated vasculitis-A Paradigm Shift"
Nice, France - 3/27/2014
"Complement-mediated renal diseases: clinical aspects, laboratory evaluation, and treatment considerations"
Belgium - 3/19/2014
"Complement-mediated renal diseases: clinical aspects, laboratory evaluation, and treatment considerations."
Brugge, Belgium - 3/19/2014
"ANCA vasculitis"
Santo Domingo, Dominican Republic - 2/27/2014
"Membranoproliferative glomerulonephritis"
Santo Domingo, Dominican Republic - 2/27/2014
"C3 Nephropathy"
Italy - 1/30/2014
"Rituximab associated with mycophenolate: the LUNAR trial experience"
Istanbul, Turkey - 5/18/2013
"Anti CD20: emerging treatment strategies of immune-mediated glomerular disease"
Istanbul, Turkey - 5/18/2013
"Persistent post-infectious glomerulonephritis: does it exist?"
Istanbul, Turkey - 5/18/2013
"Persistent post-infectious GN: does it exist?"
Sardinia, Italy - 4/30/2013
"Treatment of ANCA associated vasculitis".
North Shore University Hospital, New York, NY - 4/27/2013
"Possible therapeutic strategies based on pathophysiological mechanisms in Membranous Nephropathy"
Turin - 1/17/2013
The Efficacy of Rituximab vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE TRIAL
San Diego - 11/3/2012
A Pilot Study to Determine the Dose and Effectiveness of H.P.Acthar® Gel in Subjects Nephrotic Syndrome due to Idiopathic Membranous Nephropathy.
San Diego - 11/3/2012
Do anti-phospholipiase A2 receptor antibodies predict recurrence of membranous nephropathy after transplantation?
San Diego - 11/2/2012
"The Use of Biologics in Clinical Nephrology"
Turin, Italy - 1/19/2012
"Idiopathic membranous nephropathy-biomarker approach".
San Diego, CA - 12/14/2011
"Idiopathic membranous nephropathy-biomarker approach"
San Diego, CA - 12/14/2011
"MPGN-a proposal to a new classification"
Yazd - 11/21/2011
"ANCA vasculitis-treatment"
Yazd - 11/21/2011
"B-cell targeted therapy in Membranous Nephropathy."
Yazd - 11/21/2011
Join now to see all

Other

The Authors Reply
Fernando Fervenza, MD, Kidney International
https://www.doximity.com/articles/0d06e5eb-70ad-4a29-8688-037c2b736df2
UpToDate, Wolters Kluwer Health - 2012-09-17
Emerging Indications for the use of Rituximab in Glomerular Disease.
Kattah AG, Fervenza FC, NephSAP Volume 11, Number 3
1/1/2012
Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis
Fervenza FC, Sethi S
http://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoprolifer
UpToDate, Wolters Kluwer Health - 2012-09-12

Authored Content

The Authors ReplyAugust 2018
Congophilic Fibrillary Glomerulonephritis: A Case SeriesJune 2018

Press Mentions

Two Kidney Disease Therapies Square off in MENTOR TrialAugust 20th, 2019
Rituximab Tops Cyclosporine in Membranous NephropathyJuly 3rd, 2019
Rituxan Has Promise in Idiopathic NephropathyNovember 6th, 2017
Join now to see all

Grant Support

Membranous Nephropathy Observational Cohort StudyNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
Pulse Dexamethasone Over 48 Weeks For Podocyte DiseasesNational Center For Research Resources2005
Pulse Dexamethasone In Focal Segmental GlomerulosclerosisNational Center For Research Resources2004–2005